N-(n-butyl)-N-(2-methoxyethyl)amine | 58203-00-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(n-butyl)-N-(2-methoxyethyl)amine
• 英文别名: Butyl-<2-methoxy-aethyl>-amin；Butyl(2-methoxyethyl)amine；N-(2-methoxyethyl)butan-1-amine
• CAS: 58203-00-2
• 化学式: C₇H₁₇NO
• mdl: MFCD01098514
• 分子量: 131.218
• InChiKey: KBFNFQKDHFXGNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(n-butyl)-N-(2-methoxyethyl)amine 在 对甲苯磺酰叠氮 、 dirhodium(II) tetrakis(perfluorobutyrate) 、 水 、 sodium hydride 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 {[Butyl-(2-methoxy-ethyl)-carbamoyl]-hydroxy-methyl}-phosphonic acid diethyl ester
  参考文献：
  名称：

  Rh(II)-Catalyzed Intramolecular C−H Insertion of Diazo Substrates in Water:  Scope and Limitations

  摘要：

  Preferential Rh(II) carbenoid intramolecular C-H versus O-H insertion derived from R-diazo-acetamides can be achieved in water by using an appropriate combination of the catalyst and amide groups, which creates a larger hydrophobic environment around the reactive carbenoid center.

  DOI：

  10.1021/jo060397a
• 作为产物：
  描述：

  在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 N-(n-butyl)-N-(2-methoxyethyl)amine
  参考文献：
  名称：

  Rh(II)-Catalyzed Intramolecular C−H Insertion of Diazo Substrates in Water:  Scope and Limitations

  摘要：

  Preferential Rh(II) carbenoid intramolecular C-H versus O-H insertion derived from R-diazo-acetamides can be achieved in water by using an appropriate combination of the catalyst and amide groups, which creates a larger hydrophobic environment around the reactive carbenoid center.

  DOI：

  10.1021/jo060397a

文献信息

• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20150336962A1

  公开（公告）日：2015-11-26

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

  这里描述了化合物的公式（00A）及其作为Janus激酶抑制剂的使用方法。
• [EN] SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY<br/>[FR] DÉRIVÉS DE 1,3,4-THIADIAZOLE SPIRO-CONDENSÉS POUR INHIBER L'ACTIVITÉ DE LA KINÉSINE KSP
  申请人：SCHERING CORP

  公开号：WO2009052288A1

  公开（公告）日：2009-04-23

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I [Chemical formula should be inserted here as it appears on abstract in paper form.]

  本发明涉及以下式（I）的化合物（其中X、R1、R2、R3、p、E、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药学上可接受的组合物），单独或与一个或多个额外治疗剂的组合物，并且涉及它们在抑制KSP动力蛋白活性以及治疗与KSP动力蛋白活性相关的细胞增殖性疾病或紊乱的用途的方法。Formula I [化学式应按照纸质形式中的摘要插入在此处。]
• [EN] COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY<br/>[FR] COMPOSÉS POUR INHIBER L'ACTIVITÉ DE LA KINÉSINE KSP
  申请人：SCHERING CORP

  公开号：WO2009061596A1

  公开（公告）日：2009-05-14

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, R27, R28, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

  本发明涉及以下式的化合物（其中X、R1、R2、R3、R27、R28、p、E、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药学上可接受的组合物），单独或与一个或多个额外治疗剂联合使用的方法，以抑制KSP动力蛋白酶活性，并用于治疗与KSP动力蛋白酶活性相关的细胞增殖性疾病或紊乱。
• [EN] PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS<br/>[FR] DÉRIVÉS DE PYRAZOLYLE UTILES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：NOVARTIS AG

  公开号：WO2021124222A1

  公开（公告）日：2021-06-24

  The present application provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; method for manufacturing said compound, and its therapeutic uses. The present application further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本申请提供了化合物的公式(I)或其立体异构体，或其对映异构体，或其可接受的药物盐，或其对映异构体的可接受的药物盐，或其对映异构体的可接受的药物盐；制造该化合物的方法及其治疗用途。本申请还提供了药理活性剂的组合以及包含该化合物的药物组合物。
• [EN] SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS<br/>[FR] DÉRIVÉS DE SPIRO 1,3,4-THIADIAZOLINE INHIBITEURS DE KSP
  申请人：SCHERING CORP

  公开号：WO2010132520A1

  公开（公告）日：2010-11-18

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

  本发明涉及下式（I）的化合物（其中X、R1、R2、R3、p、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药用组合物），单独或与一个或多个额外治疗剂结合使用的方法，以及用于抑制KSP肌动蛋白活性和治疗与KSP肌动蛋白活性相关的细胞增殖性疾病或疾病的方法。